Lonza has begun the implementation of its previously announced new organization structure for its CDMO business.

The moves are part of an overall company strategy for a simplified organizational structure and is based on four key initiatives: (1) focus on its CDMO business; (2) reshape its operating model; (3) elevate execution in manufacturing and engineering; and (4) expand through an impartial approach to buy and build. 

The organizational structure for its CDMO business evolved from three divisions with nine underlying business units to a simplified set-up with three integrated business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The simplified organization has been designed to enhance customer experience, provide scalability for future growth, and strengthen its multimodality offering, according to the company. After the initiation, the three new platforms are as follows:

• Integrated Biologics, led by Gordon Bates, advances Lonza’s integrated offering and comprises Mammalian and Drug-Product Services;
• Advanced Synthesis, led by Christian Seufert, combines hybrid chemistry and biology solutions and comprises the former Small Molecules Division and Bioconjugates.
• Specialized Modalities, led by Daniel Palmacci, pioneers and scales technologies, including Cell & Gene Technologies, mRNA, Microbial, and Bioscience.

Within the new structure, the business unit layer has been removed, and the three business platforms now each directly manage multiple technology platforms. Continuing to operate in its current structure, the Capsules & Health Ingredients (CHI) business will continue to operate in its existing structure and is now led by Jean-Christophe Hyvert. Lonza plans to part ways with the business at the appropriate time and in the best interests of shareholders and stakeholders while ensuring CHI continues to serve its customers and deliver profitable growth as the global market leader in its space.

Source: Lonza